[go: up one dir, main page]

LU91036I2 - Adefovir dipivoxil et ses dérivés pharmaceutiquement acceptables (hepsera) - Google Patents

Adefovir dipivoxil et ses dérivés pharmaceutiquement acceptables (hepsera)

Info

Publication number
LU91036I2
LU91036I2 LU91036C LU91036C LU91036I2 LU 91036 I2 LU91036 I2 LU 91036I2 LU 91036 C LU91036 C LU 91036C LU 91036 C LU91036 C LU 91036C LU 91036 I2 LU91036 I2 LU 91036I2
Authority
LU
Luxembourg
Prior art keywords
hepsera
pharmaceutically acceptable
acceptable derivatives
adefovir dipivoxil
agents
Prior art date
Application number
LU91036C
Other languages
English (en)
Original Assignee
Acad Of Science Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24335088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acad Of Science Czech Republic filed Critical Acad Of Science Czech Republic
Publication of LU91036I2 publication Critical patent/LU91036I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LU91036C 1990-09-14 2003-08-13 Adefovir dipivoxil et ses dérivés pharmaceutiquement acceptables (hepsera) LU91036I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58390690A 1990-09-14 1990-09-14

Publications (1)

Publication Number Publication Date
LU91036I2 true LU91036I2 (fr) 2003-10-13

Family

ID=24335088

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91036C LU91036I2 (fr) 1990-09-14 2003-08-13 Adefovir dipivoxil et ses dérivés pharmaceutiquement acceptables (hepsera)

Country Status (12)

Country Link
US (2) US5663159A (fr)
EP (1) EP0481214B1 (fr)
JP (1) JP3164385B2 (fr)
AT (1) ATE167679T1 (fr)
BR (1) BR1100467A (fr)
CA (1) CA2051239C (fr)
DE (2) DE69129650T2 (fr)
DK (1) DK0481214T3 (fr)
ES (1) ES2118069T3 (fr)
HK (1) HK1010053A1 (fr)
LU (1) LU91036I2 (fr)
NL (1) NL300131I2 (fr)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510020A (ja) * 1991-03-29 1994-11-10 ユニバーシティ・オブ・フロリダ 混成リン酸エステル誘導体を経た標的への薬剤供給
DE4142570A1 (de) * 1991-12-21 1993-06-24 Basf Ag Glykolaldehyd- und milchsaeurederivate, deren herstellung und verwendung
GB9205917D0 (en) * 1992-03-18 1992-04-29 Smithkline Beecham Plc Pharmaceuticals
FR2691463A1 (fr) * 1992-05-25 1993-11-26 Centre Nat Rech Scient Dérivés nucléotidiques, leur préparation et leur application en thérapeutique.
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5770725A (en) * 1992-05-25 1998-06-23 Gosselin; Gilles Phosphotriester type biologically active compounds
US5849905A (en) * 1994-11-23 1998-12-15 Centre National De La Recherche Scientifique Biologically active phosphotriester-type nucleosides and methods for preparing same
US6020482A (en) * 1992-05-25 2000-02-01 Gosselin; Gilles Phosphotriester type biologically active compounds
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5817647A (en) * 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
CA2126601A1 (fr) * 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Derives d'ester phosphonate de nucleotide
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
JP4086314B2 (ja) * 1993-09-17 2008-05-14 ギリアード サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
CA2171868A1 (fr) * 1993-09-17 1995-03-23 Petr Alexander Methode pour le dosage de composes therapeutiques
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5627185A (en) * 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
AU1427097A (en) * 1995-12-29 1997-07-28 Gilead Sciences, Inc. Nucleotide analogs
US5717095A (en) * 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
AU713374B2 (en) * 1996-07-26 1999-12-02 Gilead Sciences, Inc. Nucleotide analogs
CA2261619C (fr) * 1996-07-26 2006-05-23 Gilead Sciences, Inc. Analogues de nucleotides
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
EP1256585B1 (fr) * 1997-07-25 2004-09-29 Gilead Sciences, Inc. Procédé de préparation de la 9-(2-(diéthylphosphonomethoxy)éthyl)-adénine
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
TR200200137T2 (tr) * 1997-07-25 2002-09-23 Gilead Sciences, Inc. Nükleotid analog kompozisyonlar.
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
ES2401070T3 (es) * 1998-03-06 2013-04-16 Metabasis Therapeutics, Inc. Nuevos profármacos para compuestos que contienen fósforo
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
PT1431304E (pt) * 1998-08-10 2015-03-09 Novartis Ag Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
ES2272268T3 (es) * 1999-03-05 2007-05-01 Metabasis Therapeutics, Inc. Nuevos profarmacos que contienen fosforo.
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
AU7361400A (en) 1999-09-08 2001-04-10 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
JP4993649B2 (ja) 1999-12-03 2012-08-08 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア サン ディエゴ ホスホネート化合物
IL150062A0 (en) * 1999-12-17 2002-12-01 Ariad Pharma Inc Proton pump inhibitors
US20020056123A1 (en) * 2000-03-09 2002-05-09 Gad Liwerant Sharing a streaming video
KR100767432B1 (ko) 2000-07-21 2007-10-17 길리애드 사이언시즈, 인코포레이티드 포스포네이트 뉴클레오티드 유사체의 전구 약물과 그것의 선택 및 제조 방법
MY141789A (en) * 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
CZ297267B6 (cs) 2001-06-29 2006-10-11 Ústav organické chemie a biochemie AV CR Deriváty pyrimidinu nesoucí fosfonátovou skupinu,zpusob jejich prípravy, jejich pouzití pro lécbu a farmaceutické prípravky tyto látky obsahující
JP4476811B2 (ja) 2002-05-13 2010-06-09 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ
WO2003095665A2 (fr) 2002-05-13 2003-11-20 Metabasis Therapeutics, Inc. Procede d'elaboration de promedicaments cycliques de pmea et de pmpa
BR0314695A (pt) * 2002-09-26 2005-08-09 Lg Life Sciences Ltd Composto, processo para preparar um composto, processo para preparar um estereoisÈmero de um composto, composição para o tratamento de doenças virais, e, composição para o tratamento da hepatite b
WO2004035577A2 (fr) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Composes tricycliques pre-organises inhibiteurs d'integrase
MXPA05004504A (es) 2002-10-31 2005-08-16 Metabasis Therapeutics Inc Nuevos di-esteres de fosfato ciclicos de 1,3-propano-1-aril-dioles y su uso en la preparacion de profarmacos.
AU2003284800A1 (en) * 2002-11-12 2004-06-03 Tianjin Kinsly Pharmaceutical Co., Ltd. A new crystal form of adefovir dipivoxil and its composition
US20060246130A1 (en) 2003-01-14 2006-11-02 Dahl Terrence C Compositions and methods for combination antiviral therapy
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
CA2527805C (fr) 2003-06-16 2012-08-21 Institute Of Organic Chemistry And Biochemistry, Academy Of Sciences Of The Czech Republic Composes de pyrimidine a groupes phosphonate, en tant qu'analogues nucleotidiques antiviraux
US20050065171A1 (en) * 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
NZ544988A (en) * 2003-07-30 2009-11-27 Gilead Sciences Inc Nucleobase phosphonate analogs for antiviral treatment
ATE433974T1 (de) * 2003-09-19 2009-07-15 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
US7829552B2 (en) * 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
WO2006128058A2 (fr) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Composes thyromimetiques utilises pour traiter les maladies hepatiques graisseuses
AU2004312546B2 (en) * 2003-12-30 2010-10-14 Gilead Sciences, Inc. Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
US20080153783A1 (en) * 2004-01-12 2008-06-26 Gilead Sciences, Inc. Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use
WO2005070901A2 (fr) * 2004-01-12 2005-08-04 Gilead Sciences, Inc. Composes antiviraux de phosphonate de pyrimidyle et procedes d'utilisation
WO2005090370A1 (fr) 2004-02-05 2005-09-29 The Regents Of The University Of California Agents pharmacologiquement actifs contenant des phosphonates esterifies, et leurs procedes d'utilisation
JP2007523180A (ja) * 2004-02-17 2007-08-16 エルジー・ライフ・サイエンシーズ・リミテッド Ｈｉｖ感染治療に有用なヌクレオシドホスホネート誘導体
ATE411030T1 (de) * 2004-04-14 2008-10-15 Gilead Sciences Inc Phosphonatanaloga von hiv- integrasehemmerverbindungen
CN103374041B (zh) 2004-06-08 2017-05-10 症变治疗公司 路易斯酸介导的环状酯的合成
CN100338080C (zh) * 2004-06-16 2007-09-19 山东中科泰斗化学有限公司 9－[2－(膦羧基甲氧基)乙基]腺嘌呤双环醇酯及其制备方法
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
PL382845A1 (pl) 2004-07-16 2008-01-21 Gilead Sciences, Inc. Związki przeciwwirusowe
EP1778251B1 (fr) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Conjugues de phosphonate nucleosidique comme agents anti-vih
EP2842559A3 (fr) * 2005-04-08 2015-03-18 Chimerix, Inc. Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
JP2008535862A (ja) 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
TW200716632A (en) * 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
EP1890768A2 (fr) * 2005-05-26 2008-02-27 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant de l'acide phosphinique
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN100526315C (zh) 2005-06-16 2009-08-12 浙江医药股份有限公司新昌制药厂 N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
TW200738742A (en) * 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (zh) * 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
US20090148407A1 (en) 2005-07-25 2009-06-11 Intermune, Inc. Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
WO2007014352A2 (fr) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Composes antiviraux
JP2009537546A (ja) * 2006-05-16 2009-10-29 ギリアード サイエンシーズ， インコーポレイテッド インテグラーゼ阻害剤
ES2531315T3 (es) * 2006-07-07 2015-03-12 Gilead Sciences Inc Compuestos de fosfinato antivíricos
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
NZ573888A (en) * 2006-07-21 2012-02-24 Gilead Sciences Inc Aza-peptide protease inhibitors
US7723380B2 (en) * 2006-07-21 2010-05-25 Gilead Sciences, Inc. Antiviral protease inhibitors
FR2908133B1 (fr) * 2006-11-08 2012-12-14 Centre Nat Rech Scient Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
CN101190927B (zh) * 2006-11-30 2012-04-18 天津天士力集团有限公司 9-[2-(膦酰甲氧)乙基]腺嘌呤单特戊酰氧甲酯的制备方法
PT2514750E (pt) 2007-06-18 2014-01-23 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
ITMI20071594A1 (it) * 2007-08-02 2009-02-03 Solmag Spa Forma cristallina monoidrata di adefovir dipivoxil
CN105055432A (zh) * 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
WO2009120358A1 (fr) * 2008-03-27 2009-10-01 Nektar Therapeutics Conjugués oligomère-base azotée
ES2398684T3 (es) 2008-04-23 2013-03-21 Gilead Sciences, Inc. Análogos de carbanucleósido para el tratamiento antiviral
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
ES2393962T3 (es) * 2008-07-08 2013-01-03 Gilead Sciences, Inc. Sales de compuestos inhibidores del VIH.
KR20100031045A (ko) * 2008-09-11 2010-03-19 씨제이제일제당 (주) 아데포비어 디피복실의 정제방법
KR20100032803A (ko) 2008-09-18 2010-03-26 씨제이제일제당 (주) 아데포비어디피복실의 개선된 제조방법
JP2012505897A (ja) * 2008-10-15 2012-03-08 インターミューン・インコーポレーテッド 治療用抗ウイルス性ペプチド
TR201109333T1 (tr) 2009-03-26 2012-01-23 Daewoong Pharmaceutical Co. Ltd. Adefovir dipivoksilin yeni kristal formları ve bunların hazırlama işlemleri.
SI2430014T1 (sl) 2009-05-13 2015-10-30 Gilead Pharmasset Llc Protivirusne spojine
WO2011011519A1 (fr) 2009-07-21 2011-01-27 Chimerix, Inc. Composés, compositions et procédés pour traiter des troubles oculaires
ES2614651T3 (es) 2009-09-21 2017-06-01 Gilead Sciences, Inc. Análogos de carbanucleósido 2' -fluorosustituidos para tratamiento antiviral
MX2012003126A (es) 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011041551A1 (fr) * 2009-10-01 2011-04-07 Intermune, Inc. Peptides antiviraux thérapeutiques
EP2343056A1 (fr) 2009-12-30 2011-07-13 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Production d'une dispersion solide stable d'adefovir dipivoxil sous forme amorphe.
HUE032860T2 (en) 2010-02-12 2017-11-28 Chimerix Inc A method for treating a virus infection
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
CA2797601A1 (fr) 2010-04-26 2011-11-10 Chimerix, Inc. Methodes de traitement d'infections retrovirales et regimes posologiques associes
CN101812090B (zh) * 2010-05-10 2013-08-14 浙江车头制药股份有限公司 一种阿德福韦单酯的制备方法
WO2011146817A1 (fr) 2010-05-21 2011-11-24 Gilead Sciences, Inc. Inhibiteurs des virus flaviviridae hétérocycliques
UY33479A (es) 2010-07-02 2012-01-31 Gilead Sciences Inc Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento
PT2588450T (pt) 2010-07-02 2017-08-03 Gilead Sciences Inc Derivados do ácido naft-2-ilacético para tratamento da sida
EP2805960A1 (fr) 2010-07-19 2014-11-26 Gilead Sciences, Inc. Procédés pour la préparation de promédicaments de phosphoramidate pur diastéromérique
CN101891767B (zh) * 2010-07-21 2012-05-23 浙江贝得药业有限公司 一种阿德福韦酯的制备方法
AP3269A (en) 2010-07-22 2015-05-31 Gilead Sciences Inc Methods and compounds for treating paramyxoviridaevirus infections
WO2012032541A1 (fr) 2010-09-06 2012-03-15 Matrix Laboratories Ltd Pseudopolymorphe d'adéfovir dipivoxil
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
MX2013003179A (es) 2010-09-20 2013-04-24 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2 '-fluoro para tratamiento antiviral.
CN102093417B (zh) * 2010-11-15 2012-11-28 济南久创化学有限责任公司 一种可制备核苷膦酸类药物的化合物及其制备方法
SG10201509456SA (en) 2010-11-17 2015-12-30 Gilead Pharmasset Llc Antiviral compounds
EP2646453A1 (fr) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Composés
MX2013006127A (es) * 2010-12-10 2013-09-26 Sigmapharm Lab Llc Composiciones sumamente estables de analogos nucleotidicoas oralmente activos o profarmacos analogos nucleotidicos oralmente activos.
EP2697241B1 (fr) 2011-04-13 2019-06-12 Gilead Sciences, Inc. Analogues de n-nucléoside de pyrimidine 1'-substitués pour un traitement antiviral
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
PT2729448E (pt) 2011-07-06 2015-12-02 Gilead Sciences Inc Compostos para o tratamento de vih
SG2014011548A (en) 2011-08-16 2014-09-26 Gilead Sciences Inc Tenofovir alafenamide hemifumarate
PT3431477T (pt) 2011-11-16 2020-12-15 Gilead Pharmasset Llc Imidazolilimidazolos condensados como compostos antivirais
ES2734495T3 (es) 2011-12-22 2019-12-10 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
JP6242378B2 (ja) * 2012-03-13 2017-12-06 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体
JP5911638B2 (ja) 2012-04-20 2016-04-27 ギリアード サイエンシーズ， インコーポレイテッド ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用
EP2846788A1 (fr) 2012-05-11 2015-03-18 Akron Molecules AG Utilisation de composés pour le traitement de la douleur
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN102977146B (zh) * 2012-11-20 2016-04-20 广东肇庆星湖生物科技股份有限公司 一种腺嘌呤衍生物的合成方法
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
WO2014143643A1 (fr) 2013-03-15 2014-09-18 The Regents Of The University Of California, A California Corporation Diesters phosphonates nucléosidiques acycliques
CN104151360B (zh) * 2013-05-14 2019-02-22 北京美倍他药物研究有限公司 磷酸/膦酸衍生物及其医药用途
CN105705508B (zh) * 2013-12-23 2017-09-01 四川海思科制药有限公司 非环核苷磷酸酯类衍生物及其制备方法与在医学上的应用
CN106061984A (zh) 2014-02-13 2016-10-26 配体药物公司 前药化合物及其用途
WO2015130964A1 (fr) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Composés thérapeutiques
WO2015197006A1 (fr) * 2014-06-25 2015-12-30 四川海思科制药有限公司 Composé thioester d'acide aminé substitué, et composition et application de celui-ci
EP3164136A4 (fr) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Composés de promédicaments et leurs utilisations
AU2015317972B2 (en) 2014-09-15 2019-10-17 The Regents Of The University Of California Nucleotide analogs
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
WO2017048956A1 (fr) 2015-09-15 2017-03-23 The Regents Of The University Of California Analogues nucléotidiques
BR112018005048B8 (pt) 2015-09-16 2021-03-23 Gilead Sciences Inc uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae
CN105294762A (zh) * 2015-11-13 2016-02-03 中国药科大学 阿德福韦酯杂质的制备方法
CN106800573B (zh) * 2015-11-25 2020-03-10 四川海思科制药有限公司 一种核苷酸膦酸酯一水合物及其制备方法和在医药上的应用
KR102180740B1 (ko) 2016-08-19 2020-11-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
WO2018039157A1 (fr) * 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Promédicaments antiviraux du ténofovir
ES2992772T3 (en) 2016-09-28 2024-12-18 Gilead Sciences Inc Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection
WO2018094265A2 (fr) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Méthodes de traitement de glycogénose
EP3372227A1 (fr) 2017-03-06 2018-09-12 MH10 Spolka z ograniczona odpowiedzialnoscia Formulation de comprimé d'adéfovir dipivoxil
ES2961460T3 (es) 2017-03-14 2024-03-12 Gilead Sciences Inc Métodos para tratar las infecciones por coronavirus felinas
JP2020518578A (ja) 2017-05-01 2020-06-25 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態
JP7168660B2 (ja) 2017-06-05 2022-11-09 バイキング・セラピューティクス・インコーポレイテッド 線維症の処置のための組成物
EP3651734B1 (fr) 2017-07-11 2024-11-13 Gilead Sciences, Inc. Composition comprenant un inhibiteur de rna polymerase et de la cyclodextrine pour traiter des infections virales
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
JP2021509907A (ja) 2018-01-09 2021-04-08 リガンド・ファーマシューティカルズ・インコーポレイテッド アセタール化合物およびその治療的使用
WO2019161017A1 (fr) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Dérivés de pyridine et leur utilisation pour le traitement d'une infection par le vih
CN116854630A (zh) 2018-02-16 2023-10-10 吉利德科学公司 用于制备可用于治疗逆转录病毒科病毒感染的治疗性化合物的方法和中间体
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
TWI842721B (zh) 2018-07-16 2024-05-21 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
JP2022510691A (ja) 2018-12-05 2022-01-27 バイキング・セラピューティクス・インコーポレイテッド 線維症及び炎症の処置のための組成物
JP2023500794A (ja) 2019-10-17 2023-01-11 エーアイ‐バイオファーマ 抗ウイルス薬および肝臓標的薬
EP4065116A1 (fr) 2019-11-26 2022-10-05 Gilead Sciences, Inc. Inhibiteurs de capside pour la prévention du vih
WO2021154687A1 (fr) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Procédés de traitement d'infections par sras cov-2
CN115298181B (zh) 2020-03-12 2024-08-16 吉利德科学公司 制备1’-氰基核苷的方法
CA3172483A1 (fr) 2020-04-06 2021-10-14 Scott Ellis Formulations d'inhalation d'analogues de carbanucleosides a substitution 1'-cyano
CA3179226A1 (fr) 2020-05-29 2021-12-02 Tomas Cihlar Methodes de traitement par remdesivir
AU2021296841B2 (en) 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
AU2021296607B2 (en) 2020-06-25 2024-07-25 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
LT4204421T (lt) 2020-08-27 2024-06-25 Gilead Sciences, Inc. Virusinių infekcijų gydymui skirti junginiai ir būdai
EP4341266A1 (fr) 2021-05-21 2024-03-27 Gilead Sciences, Inc. Dérivés pentacycliques en tant qu'inhibiteurs du virus zika
CN113880883A (zh) * 2021-11-11 2022-01-04 奥锐特药业股份有限公司 核苷类磷酸酯前药的制备方法
KR20240113577A (ko) 2021-12-03 2024-07-22 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
KR20240117588A (ko) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
WO2023167944A1 (fr) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Composés et méthodes pour traiter des infections virales

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1135029A (en) * 1965-06-08 1968-11-27 Upjohn Co Improvements in or relating to cyclic phosphates and the manufacture thereof
US3929840A (en) * 1972-07-14 1975-12-30 Merck & Co Inc Labile esters of ({31 )(cis-1,2-epoxypropyl)phosphonic
US4816447A (en) * 1981-08-26 1989-03-28 Merck & Co., Inc. Anti-viral guanine compounds
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
NZ222553A (en) * 1986-11-18 1991-07-26 Bristol Myers Co Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
AU8092587A (en) * 1986-11-18 1988-05-19 Bristol-Myers Squibb Company Synthesis of purin-9-ylalkylenoxymethyl phosphonic acids
AU610344B2 (en) * 1988-02-29 1991-05-16 Taiho Pharmaceutical Co., Ltd. 2'-deoxy-5-fluorouridine derivatives
EP0353955A3 (fr) * 1988-08-02 1991-08-14 Beecham Group Plc Composés chimiques
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
DE69132276T2 (de) * 1990-08-10 2001-03-01 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Verfahren zur herstellung von nukleotiden
GB9026164D0 (en) * 1990-12-01 1991-01-16 Beecham Group Plc Pharmaceuticals

Also Published As

Publication number Publication date
DE10399025I1 (de) 2003-10-23
ES2118069T3 (es) 1998-09-16
DK0481214T3 (da) 1999-02-22
HK1010053A1 (en) 1999-06-11
DE69129650D1 (de) 1998-07-30
EP0481214A1 (fr) 1992-04-22
CA2051239C (fr) 2003-03-25
EP0481214B1 (fr) 1998-06-24
DE10399025I2 (de) 2007-11-08
BR1100467A (pt) 2000-06-06
US5792756A (en) 1998-08-11
NL300131I1 (nl) 2003-10-01
ATE167679T1 (de) 1998-07-15
DE69129650T2 (de) 1999-03-25
JPH04230694A (ja) 1992-08-19
JP3164385B2 (ja) 2001-05-08
CA2051239A1 (fr) 1992-03-15
US5663159A (en) 1997-09-02
NL300131I2 (nl) 2004-02-02

Similar Documents

Publication Publication Date Title
LU91036I2 (fr) Adefovir dipivoxil et ses dérivés pharmaceutiquement acceptables (hepsera)
JP2900064B2 (ja) ヌクレオシド アナローグ類
CA2623522C (fr) 4'-nucleosides modifies comme agents antiviraux
US7018989B2 (en) Chemical compounds
JP3421335B2 (ja) 鏡像異性的に純粋なβ−Ｄ−（−）−ジオキソラン−ヌクレオシド
US7820631B2 (en) Anti-viral pyrimidine nucleoside analogues
US7019135B2 (en) Anti-viral pyrimidine nucleoside analogues
KR930006036A (ko) 퓨린 및 피리미딘의 불포화 비환식 포스포네이트 유도체
NZ223990A (en) Acylated 2',3'-dideoxynucleosides and pharmaceutical compositions
HU195657B (en) Process for production of carbocyclic pirin nucleorids and medical compounds containing them
ES2187989T3 (es) Composicion de analogos de nucleotido y procedimiento de sintesis.
FR2374334A1 (fr) Nouveaux nucleosides utiles comme medicaments et procede pour leur preparation
MY103801A (en) Dideoxydidehydrocarbocyclic nucleosides
RU96118248A (ru) 3'-замещенное производное нуклеозида
De Clercq Antiviral activity of 5-substituted pyrimidine nucleoside analogues
KR880012628A (ko) 치료학적인 뉴클레오시드
JPH0680688A (ja) ４’−メチルヌクレオシド誘導体
EP0340778A3 (fr) Prodrogues de 2',3'-didéshydro-2',3'-didésoxynucléosides
DK1135401T3 (da) Glycerylnucleotider, fremgangsmåder til deres fremstilling og deres anvendelse
KR930702374A (ko) 안티 센스 핵산 유도체
CA1303032C (fr) Nucleosides antiviraux
FR2444038A1 (fr) Derives de pyrazolo(1,5-c)quinazoline utiles comme medicaments et leurs procedes de preparation
EP0317728A3 (fr) Utilisation de dérivés de 9-(beta-D-arabinofuranosyl)adénine pour la préparation des compositions pharmaceutiques pour le traitement du SIDA
KR900016235A (ko) 옥세타노신의 인산에스테르 유도체와 그 제조방법 및 용도